FORT WORTH, Texas, Sept. 21 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced today its subsidiary Wound Care Innovations, LLC, will exhibit at the Georgetown University Hospital’s Team Approach to Diabetic Limb Salvage (DLS) conference in Washington, D.C. September 24th-26th.
Wound Care Innovations’ advanced wound care collagen product, CellerateRx(R), is featured in an abstract by Dr. Matthew Regulski, DPM, Director of the Wound Care Center of Ocean County, NJ, that will be presented at DLS 2009. The abstract, “Activated Collagen: An Evidence Based Study in Human Leg Ulcers”, provides data showing that all activated collagen treated wounds were healed by five weeks, while the control wounds were approximately 80% healed within twelve weeks.
About Wound Management Technologies, Inc.:
Wound Management Technologies, through its subsidiary Wound Care Innovations, markets and distributes wound care products to the healthcare market under patented technology licensed to the company. The company is positioned and seeks to be a leading provider of wound care products. The company’s corporate headquarters are in Fort Worth, Texas, For more information please visit the company’s website at www.celleraterx.com.
A profile for investors can be accessed at http://www.hawkassociates.com/clients/profile/wnmd.cfm.
Safe Harbor Statement Under The Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company’s operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company’s SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE Wound Management Technologies, Inc.
CONTACT: Product information: Cathy Bradshaw, +1-954-315-9242; and
Shareholder relations: Lucy Singleton, +1-817-820-7080; and Investor
relations: Frank Hawkins or Julie Marshall, Hawk Associates,
+1-305-451-1888, woundmanagement@hawkassociates.com
Web site: http://www.celleraterx.com/
